Globally

Globally, Epithelial ovarian cancer is the seventh most common type of cancer in women and  the eighth most common cause of cancer death, with five – year survival rate of less than 45% 1. Most of  epithelial ovarian cancer patients were diagnosed at the late stage or at  metastatic,stage 2. Early diagnosis and targeted therapy have been an important and challenging area in the treatment of epithelial ovarian cancer. Till now, there hasn’t been any breakthrough 3-11. At present, the commonest way to diagnose ovarian cancer and monitor its recurrence is  by serum CA125 12-14. However, it has significant limitation in that, it has low specificity , and it’s elevated not only in the patients with epithelial ovarian cancer but also in patients with ovarian endometriosis and other benign diseases 15,. Biological targeted technology has proven to be a valuable tool for the diagnosis and treatment of many diseases 16, including epithelial ovarian cancer 17.